Lexicon Pharmaceuticals, Inc. (LXRX)

1.7400 +0.0400 (+2.35%) 收市：04:00PM EDT

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Boulevard
11th Floor
The Woodlands, TX 77381
United States
281 863 3000
https://www.lexpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 285

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Lonnel Coats	CEO & Director	1.14M	無	1965
Mr. Jeffrey L. Wade J.D.	President & CFO	752.05k	無	1965
Mr. Brian T. Crum	Senior VP, General Counsel & Secretary	596.48k	無	1973
Dr. Alan J. Main Ph.D.	Executive Vice President of Innovation & Chemical Sciences	576.96k	無	1954
Dr. Craig B. Granowitz M.D., Ph.D.	Senior VP & Chief Medical Officer	652.48k	無	1965
Ms. Kristen L. Alexander	Vice President of Finance & Accounting	無	無	1968
Ms. Lisa M. DeFrancesco	Head of Investor Relations & Corporate Strategy	無	無	1980
Mr. Dixon Terry	Vice President of Compliance	無	無	無
Ms. Carrie Siragusa	Vice President of Marketing	無	無	無
Ms. Desiree Gendron	Vice President of Sales & Training	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

公司管治

截至 2024年5月1日 止，Lexicon Pharmaceuticals, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：7；董事會：10；股東權利：9；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。